abstract |
The present invention relates to detection of mutations in the kinase domain of c-Src in a tumour sample from a patient. Also claimed are mutant c-Src polynucleotides comprising mutations at position 829, 1032, 1270, 1342, 1359, 1372 or 1486, and mutant c-Src polypeptides comprising mutations at residues 277, 344, 424, 448, 458 or 496. |